Cargando…

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)

Lipoprotein(a) [Lp(a)] is a well-established risk factor for cardiovascular disease, predisposing to major cardiovascular events, including coronary heart disease, stroke, aortic valve calcification and abdominal aortic aneurysm. Lp(a) is differentiated from other lipoprotein molecules through apoli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosmas, Constantine E., Bousvarou, Maria D., Papakonstantinou, Evangelia J., Tsamoulis, Donatos, Koulopoulos, Andreas, Echavarria Uceta, Rogers, Guzman, Eliscer, Rallidis, Loukianos S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487774/ https://www.ncbi.nlm.nih.gov/pubmed/37686428 http://dx.doi.org/10.3390/ijms241713622

Ejemplares similares

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2022)

Lipoprotein(a): Its Association with Calcific Aortic Valve Stenosis, the Emerging RNA-Related Treatments and the Hope for a New Era in “Treating” Aortic Valve Calcification
por: Tsamoulis, Donatos, et al.
Publicado: (2023)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

Therapeutic management of hyperlipoproteinemia (a)
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Insulin resistance and cardiovascular disease
por: Kosmas, Constantine E., et al.
Publicado: (2023)

The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease
por: Kosmas, Constantine E., et al.
Publicado: (2023)

Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Clinical trials during pandemic in primary care: Low number and low validity after one-year experience
por: Tatsioni, Athina, et al.
Publicado: (2021)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Rising trends in Takotsubo syndrome during the COVID-19 pandemic: A single center experience
por: Rallidis, Loukianos S., et al.
Publicado: (2022)

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Primary genetic disorders affecting high density lipoprotein (HDL)
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Eruptive Xanthomas Caused by Primary Type V Hyperlipoproteinemia
por: Nakamura, Yoshihiro, et al.
Publicado: (2021)

Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types
por: Ilina, Larisa N., et al.
Publicado: (2022)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017)

Management of Patients with Type V Hyperlipoproteinemia: An Uncommon Phenotype of Dyslipidemia with Chylomicronemia and Severe Hypertriglyceridemia
por: Chang, Ya-Hui, et al.
Publicado: (2022)

Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
por: Grützmacher, P., et al.
Publicado: (2017)

A rare case of COVID-19 pneumonia with severe hyperlipoproteinemia
por: Shimoda, Masafumi, et al.
Publicado: (2022)

A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment
por: Mangeshkar, Shaunak, et al.
Publicado: (2023)

ST-elevation myocardial infarction in a 39-year-old patient with “normal” coronary arteries as a thrombotic complication of COVID-19
por: Liori, Sotiria, et al.
Publicado: (2021)

An ominous triad: acute inferior ST-segment elevation myocardial infarction, right ventricular infarction, and ventricular septal rupture/dissection
por: Rallidis, Loukianos S, et al.
Publicado: (2023)

The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular Disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

SUN-056 Recurrent Pancreatitis Induced by Uncontrolled Type V Hyperlipoproteinemia
por: Rivera Rivero, Bianshly, et al.
Publicado: (2019)

Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)
por: Pallazola, Vincent A., et al.
Publicado: (2019)

Hyperlipoproteinemia (a) is associated with breast cancer in a Han Chinese population
por: Xu, Jing, et al.
Publicado: (2020)

A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia
por: Hegele, Robert A., et al.
Publicado: (2009)

Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate
por: Cicero, Arrigo F.G., et al.
Publicado: (2013)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Identification and Characterization of Two Novel Compounds: Heterozygous Variants of Lipoprotein Lipase in Two Pedigrees With Type I Hyperlipoproteinemia
por: Wang, Shuping, et al.
Publicado: (2022)

Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia
por: Georgiadou, Dimitra, et al.
Publicado: (2011)

Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities
por: Fras, Zlatko
Publicado: (2020)

Loss-of-Function Homozygous Variant in LPL Causes Type I Hyperlipoproteinemia and Renal Lipidosis
por: Wu, Hongyan, et al.
Publicado: (2023)

A Case of Hypothyroidism and Type 2 Diabetes Associated with Type V Hyperlipoproteinemia and Eruptive Xanthomas
por: Park, Jeong Rang, et al.
Publicado: (2005)

Case report of one month and 15 days old baby with type V hyperlipoproteinemia (HLP)
por: Dildar, Shabnam, et al.
Publicado: (2020)

Case of familial hyperlipoproteinemia type III hypertriglyceridemia induced acute pancreatitis: Role for outpatient apheresis maintenance therapy
por: Saleh, Mohannad Abou, et al.
Publicado: (2017)

eNOS Gene Variants and the Risk of Premature Myocardial Infarction
por: Zigra, Aggeliki-Maria, et al.
Publicado: (2013)

A Posteriori Dietary Patterns and Coronary Artery Disease in a Greek Case–Control Study
por: Dimitriou, Maria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qp4nhbf6bm3lvkjqfofr2v9htl